Celldex Therapeutics, Inc.: Pipeline of antibody-based immunotherapies/targeted therapies, including CD40 agonist achieving one of the highest systemic dose levels in the class and demonstrated single-agent clinical activity; collaboration with Merck to study combination with Keytruda (SITC 2019), ErbB3 RTK inhibitor with biomarker directed development strategy in HNSCC (ASCO 2019); KIT inhibitor targeting mast cell driven diseases (ACAII 2019) and bispecific platform—first candidate couples CD27 co-stimulation with PD-L1/PD-1 blockade (SITC).
Based in...
US - Middle Atlantic
Clinical Stage
Phase l or ll, Pre-Clinical Stage
Disease Space
Allergy, Dermatology, Immuno-Oncology, Immunotherapy, Oncology, Rare Disease
Biotechnology, Specialty Pharmaceutical
Public, USA
Market Cap
500MM - 1B
Therapeutic Modalities
Platform Technology
53 Frontage Road
Suite 220
Hampton, NJ 08827
United States

Top 10 Holders of Celldex Therapeutics, Inc.

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
BVF, Inc. 17.23 2,740,000 35.46 13F 6/30/20
BVF Partners LP 17.23 2,740,000 35.46 Stakes 6/26/20
RTW Investments LP 16.41 2,610,000 33.77 13F 6/30/20
Logos Global Management LP 12.57 2,000,000 25.88 13F 6/30/20
Redmile Group LLC 12.57 2,000,000 25.88 13F 6/30/20
Adage Capital Management LP 11.95 1,900,000 24.59 Stakes 7/14/20
Adage Capital Partners GP LLC 11.00 1,750,000 22.65 13F 6/30/20
Ikarian Capital LLC 10.36 1,647,439 21.32 13F 6/30/20
Renaissance Technologies LLC 10.29 1,637,175 21.19 13F 6/30/20
Vivo Capital LLC 10.06 1,600,000 20.70 13F 6/30/20
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2020 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.